Simulation Plus (SLP) Q2 2026: Services Backlog Climbs 18% as AI Collaborations Deepen Pharma Integration
SLP’s Q2 saw robust backlog expansion and stable software growth, underpinned by deepening AI-driven partnerships with large pharma clients. Management’s cautious guide reflects a still-fragile biopharma environment, but execution is increasingly aligned with long-term platform ambitions. Investors should watch for cross-sell traction and AI monetization as leading indicators for out-year upside.
Summary
- AI Ecosystem Integration: Strategic collaborations with top pharma signal durable demand for SLP’s scientific engines within evolving AI workflows.
- Backlog and Pipeline Strength: Services backlog rose sharply, supporting forward visibility amid a mixed renewal environment.
- Pragmatic Guidance Stance: Leadership maintains a conservative outlook despite first-half momentum, citing macro and sector fragility.
Performance Analysis
Simulation Plus delivered balanced growth across software and services, with revenue up 8% year-over-year, exceeding prior guidance. Software accounted for 60% of total revenue and posted a 9% increase, led by strong performance in discovery (AdMet Predictor, property prediction platform, up 19%) and development (GastroPlus and Monolix Suite, PBPK and PKPD modeling engines, up 12%). Clinical operations, primarily proficiency, continued to contract, now just 3% of software revenue, underscoring a legacy-to-growth mix shift.
Services revenue grew 8%, with development services representing the majority (77%) and showing double-digit growth. Ending services backlog expanded 18% to $24 million, providing solid forward coverage. Gross margin improved to 66%, driven by higher software contribution and lower amortization, while services margin remains structurally lower at 33%. The company ended the quarter with $41.8 million in cash, no debt, and reaffirmed its disciplined capital allocation posture.
- Cross-Sell Expansion: 50% of clients with >$100,000 in software spend now use two or more products, highlighting embedded upsell potential.
- Client Stability: Top 25 customers contribute 46% of software revenue, with 100% logo and 90%+ gross revenue retention, anchoring the base.
- Renewal Risk: Overall renewal rates dipped, driven by churn in smaller biopharma and pre-commercial biotech, reflecting sector cyclicality.
Despite headwinds in clinical ops and episodic churn among smaller clients, SLP’s core growth engines and backlog trends position the company for resilient performance as AI adoption broadens.
Executive Commentary
"AI is accelerating the industry's transition toward data-driven drug development workflows, and importantly, enhancing the value of trusted and validated scientific engines rather than replacing them. These capabilities are built on decades of scientific investment, deep domain expertise, validated methodologies, and integration into customer workflows and regulated environments."
Sean O'Connor, Chief Executive Officer
"Software revenue increased 9%, representing 60% of total revenue. And services revenue increased 8%, representing 40% of total revenue. We ended the quarter with 297 commercial clients achieving an average revenue per client of 124,000 and a 91% renewal rate for the quarter."
Will Frederick, Chief Financial Officer
Strategic Positioning
1. AI-Driven Pharma Collaboration
SLP’s partnerships with three top pharma companies are embedding AI agents into workflows across GastroPlus, Monolix Suite, AdMet Predictor, and Thales. These collaborations are not new relationships but represent a deepening integration, providing SLP with direct insight into real-world pharma AI adoption and future commercial models. SLP is positioning itself as the connective tissue for validated, auditable biosimulation within regulated AI-enabled drug development.
2. Cross-Sell and Ecosystem Leverage
The transition from product-focused selling to regional account management is designed to drive cross-sell and upsell, particularly among stable large pharma clients. With 50% of high-value clients purchasing two products and 23% using three, the company is building a platform effect that increases switching costs and wallet share over time. Enhanced interoperability and cloud delivery are lowering barriers for smaller clients and broadening SLP’s TAM (total addressable market, market size a company can serve).
3. Services and Backlog Visibility
Services backlog growth and a healthy pipeline support near-term revenue stability. Development services (biosimulation consulting, model development) remain the core, while MedCom (communications) services drive incremental growth. The company is shifting toward larger, more complex projects, which can create lumpiness in project count but higher average deal value and stickier client relationships.
4. AI Monetization and Proof Points
AI monetization is not expected to be material in FY26, but groundwork is being laid for fiscal 2027 and beyond. Early revenue from AI-driven discovery clients (e.g., DeepMind, Recursion) is primarily through AdMet Predictor, while future upside hinges on successful commercial rollout of integrated AI workflows. Management is focused on demonstrating incremental value that will support premium pricing and new budget sources within pharma clients.
Key Considerations
This quarter’s results reflect SLP’s evolution from a collection of modeling tools to an integrated, AI-powered biosimulation platform. Investors should weigh execution on cross-sell, backlog conversion, and AI adoption against persistent renewal volatility among smaller clients.
Key Considerations:
- AI Integration as Differentiator: SLP’s validated scientific engines and regulatory credibility are increasingly valued as pharma clients move beyond AI experimentation.
- Backlog and Pipeline Health: Services backlog growth provides forward revenue visibility, offsetting episodic project and renewal risk.
- Cross-Sell Execution: Success in moving clients from single to multi-product adoption will be a key growth lever and retention hedge.
- Renewal Rate Sensitivity: Churn among smaller biopharma and pre-commercial clients remains elevated, reflecting broader sector funding dynamics.
- Conservative Guidance Philosophy: Management is prioritizing stability and credibility over near-term upside, given macro and sector fragility.
Risks
Renewal risk among smaller clients, ongoing biopharma funding uncertainty, and the pace of AI monetization remain the most material uncertainties. Management’s cautious guide reflects sensitivity to macro shocks, regulatory changes, and potential delays in client AI adoption. Investors should also monitor margin volatility as services mix and project complexity evolve.
Forward Outlook
For Q3 2026, Simulation Plus guided to:
- Revenue between $20 and $22 million
- Adjusted EBITDA margin of 27% to 33%
- Adjusted diluted EPS between $0.20 and $0.27
For full-year 2026, management maintained guidance:
- Total revenue of $79 to $82 million (0% to 4% YoY growth)
- Software mix of 57% to 62%
- Adjusted EBITDA margin of 26% to 30%
- Adjusted diluted EPS now $0.75 to $0.85, reflecting a higher tax rate
Management highlighted:
- Momentum in backlog and new logo wins, with cross-sell and AI partnerships as key drivers.
- Fragile macro and sector environment, leading to a conservative approach on guidance raises despite first-half strength.
Takeaways
SLP’s Q2 underscores its strategic shift toward platform integration and AI-enabled workflows, with backlog strength and cross-sell progress offsetting renewal headwinds. Investors should focus on leading indicators such as backlog conversion, AI monetization milestones, and cross-sell penetration for signs of sustainable outperformance.
- Backlog Expansion: Services backlog growth supports near-term revenue visibility and validates demand for SLP’s consulting and modeling expertise.
- AI Partnerships as Moat: Deepening collaborations with large pharma clients embed SLP’s engines in next-generation drug development, raising competitive barriers.
- Watch AI Monetization and Renewal Trends: Out-year upside depends on successful AI productization and stabilization of renewal rates among smaller clients.
Conclusion
Simulation Plus is executing on its vision of an integrated, AI-powered biosimulation ecosystem, with strong backlog and strategic pharma partnerships providing ballast against sector volatility. While near-term guidance remains cautious, operational progress and platform investments position the company for long-term value creation as AI adoption in drug development accelerates.
Industry Read-Through
SLP’s results and commentary highlight the growing importance of validated, auditable scientific engines within AI-driven pharma R&D. The company’s platform approach and deep client integration signal that biosimulation vendors with regulatory credibility and cross-product interoperability are best positioned to win as AI budgets expand. Sector-wide, the shift from point solutions to ecosystem partnerships is accelerating, with backlog and cross-sell metrics emerging as critical leading indicators for both software and services providers in the life sciences technology space.